Table 1. Short-term effects of medical treatment in chronic post-embolic pulmonary hypertension.

Treatment	Administration	First author [Ref.]	Study	Duration months	Patients n	NYHA-FC	6MWD m	Effect m	PVR dyn·s−1·cm−5	Effect %
Epoprostenol	i.v.	Cabrol [6]		3	23	III–IV	280±112	+66	29±7#,¶	-21
Treprostinil	Subcutaneously	Skoro-Sajer [7]		6 or 19	25	III–IV	260±111	+59	924±347	-13
Iloprost	Inhaled	Olschewski [8]	RCT	3	57	III–IV	NA	ns	NA	ns
Sildenafil	By mouth	Ghofrani [9]		6	12	ns	312±30	+54	1935±228+	-30
Sildenafil	By mouth	Reichenberger [10]		3	104	II–IV	310±11	+51	863±38	-12
Sildenafil	By mouth	Suntharalingam [11]	RCT	3	19	II–III	339±58	+18 (ns)	734±363	-27
Bosentan	By mouth	Hoeper [12]		3	19	II–IV	340±102	+73	914±329	-33
Bosentan	By mouth	Hughes [13]		3	20	II–IV	262±106	+45	1165±392#	-21
Bosentan	By mouth	Bonderman [14]		6	16	II–IV	299±131	+92	712±213	NA
Bosentan	By mouth	Seyfarth [15]		6	12	III	319±85	+72	1008±428	NA
Bosentan	By mouth	Jaïs [16]	RCT	4	157	II–III	342±84	+2 (ns)	783	-24
Riociguat	By mouth	Ghofrani [17]	OL	3	41	II–III	390 (330–441)	+55	691 (533–844)	-29
Riociguat	By mouth	Ghofrani [18]	RCT	4	261	II–III	349	+46	785	-31

Data are presented as mean±sd or median (interquartile range), unless otherwise stated. NYHA-FC: New York Heart Association functional class; 6MWD: 6-min walking distance; PVR: pulmonary vascular resistance; RCT: randomised controlled trial; OL: open label; NA: not available; ns: not significant. ^#: total PVR; ^¶: in Woods Units·m²; ⁺: in dyn·s⁻¹·cm⁻⁵·m⁻².